Disease modeling and target identification are critical and time-consuming portions of the drug discovery process and areas where artificial intelligence (AI) is already making a substantial impact. A new opinion paper in the Cell Press journal Trends in Pharmacological Sciences traces the history of target discovery methods - from experimental approaches, to

Insilico Medicine ("Insilico"), a generative artificial intelligence (AI)-driven clinical stage drug discovery company, announced that the U.S. Food and Drug Administration (FDA) recently approved the initial investigational new drug (IND) application for ISM3091 for the treatment of patients with solid tumors. This is Insilico's first oncology program to advance to the clinical validation stage.

Insilico Medicine (Insilico), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, announced that the company has nominated a potentially best-in-class preclinical candidate targeting ENPP1 for cancer immunotherapy and the potential treatment of Hypophosphatasia (HPP).

ENPP1 is an ecto-nucleotide pyrophosphatase that plays an important role in purinergic signaling that regulates immune, cardiovascular, neurological, and hematological system functions.

The 20th anniversary edition of the CPHI Pharma Awards is now open for entries, with three new categories created to reflect the surge of innovation sweeping the industry - from new methodologies to sustainability and philanthropic initiatives.

In the last year, pharma has continued its rapid rate of innovation embracing the speed of pandemic R&D, but added to this are new social goals that aim to improve the wider world as well as bottom lines and therapeutic/device options.

Insilico Medicine, a clinical-stage generative artificial intelligence (AI)-powered drug discovery company, has integrated advanced AI chat functionality based on recent advances in large language models into its PandaOmics platform. The new feature, "ChatPandaGPT," enables researchers to have natural language conversations with the platform and efficiently navigate and analyze large datasets, facilitating the discovery of potential therapeutic targets and biomarkers in a more efficient manner.

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced that the results from Eisai's large global Phase 3 confirmatory Clarity AD clinical study of lecanemab (development code: BAN2401), an investigational anti-amyloid beta (Aβ) protofibril antibody for the treatment of mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD (collectively known as early AD) with confirmed presence of amyloid pathology in the brain,

Salvat Laboratories announced that it has submitted a New Drug Application (NDA) to the FDA for the approval of the first ocular corticosteroid formulated in a nanoemulsion for inflammation and pain in post-ocular surgery patients.

This submission comes after two successful phase III clinical trials conducted between 2020 and 2021.